Immunome, Inc. Price & Performance (IMNM)

Immunome stock, after hitting a 52-week low below $7, has rebounded over 26% in the last two weeks. Recent insider buying, including a nearly $1 million purchase by CEO Clay Siegall, signals growing executive confidence. Analyst targets remain bullish, averaging above $25, despite ongoing market volatility and clinical trial risks.123

Immunome shares have experienced significant price swings, recently gaining over 10% in a single day with volumes spiking. Despite a challenging year, several analysts have reiterated 'buy' ratings, with price targets ranging from $20 to $33. The company’s pipeline progress and strong liquidity underpin cautious optimism.456

Immunome reports robust liquidity, with $217 million in cash and equivalents and a current ratio above 4. The company’s workforce more than doubled last year, supporting its expanding pipeline, including late-stage cancer trials. Despite recent losses and negative margins, analysts see potential upside as development efforts accelerate.178